Literature DB >> 16968599

Current status of gastric MALT lymphoma.

T Wündisch1, M Stolte.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16968599     DOI： 10.1007/s11894-006-0016-6

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN： 1522-8037


× No keyword cloud information.
  52 in total

Review 1.  MALT lymphomas: a radiation oncology viewpoint.

Authors:  J Yahalom
Journal:  Ann Hematol       Date:  2001       Impact factor: 3.673

2.  Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma.

Authors:  C Copie-Bergman; P Gaulard; A Lavergne-Slove; N Brousse; J F Fléjou; K Dordonne; A de Mascarel; A C Wotherspoon
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

3.  Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways.

Authors:  Petr Starostik; Jochen Patzner; Axel Greiner; Stephan Schwarz; Jörg Kalla; German Ott; Hans Konrad Müller-Hermelink
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

4.  Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone.

Authors:  N R Schechter; C S Portlock; J Yahalom
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

5.  Genetic evidence for a clonal link between low and high-grade components in gastric MALT B-cell lymphoma.

Authors:  H Peng; M Du; T C Diss; P G Isaacson; L Pan
Journal:  Histopathology       Date:  1997-05       Impact factor: 5.087

6.  Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92.

Authors:  P Koch; F del Valle; W E Berdel; N A Willich; B Reers; W Hiddemann; B Grothaus-Pinke; G Reinartz; J Brockmann; A Temmesfeld; R Schmitz; C Rübe; A Probst; G Jaenke; H Bodenstein; A Junker; C Pott; J Schultze; A Heinecke; R Parwaresch; M Tiemann
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

7.  T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication.

Authors:  Hongxiang Liu; Hongtao Ye; Agnes Ruskone-Fourmestraux; Daphne De Jong; Stefano Pileri; Christian Thiede; Anne Lavergne; Henk Boot; Giancarlo Caletti; Thomas Wündisch; Thierry Molina; Babs G Taal; Sabattini Elena; Togliani Thomas; Pier Luigi Zinzani; Andreas Neubauer; Manfred Stolte; Rifat A Hamoudi; Ahmet Dogan; Peter G Isaacson; Ming-Qing Du
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

8.  Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome.

Authors:  Michaël Levy; Christiane Copie-Bergman; Catherine Traulle; Anne Lavergne-Slove; Nicole Brousse; Jean-François Flejou; A de Mascarel; François Hemery; Philippe Gaulard; Jean-Charles Delchier
Journal:  Am J Gastroenterol       Date:  2002-02       Impact factor: 10.864

9.  Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma.

Authors:  Berthold Streubel; Hongtao Ye; Ming-Qing Du; Peter G Isaacson; Andreas Chott; Markus Raderer
Journal:  Oncology       Date:  2004       Impact factor: 2.935

10.  Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32).

Authors:  Q Zhang; R Siebert; M Yan; B Hinzmann; X Cui; L Xue; K M Rakestraw; C W Naeve; G Beckmann; D D Weisenburger; W G Sanger; H Nowotny; M Vesely; E Callet-Bauchu; G Salles; V M Dixit; A Rosenthal; B Schlegelberger; S W Morris
Journal:  Nat Genet       Date:  1999-05       Impact factor: 38.330
View more
  1 in total

1.  Clinical analysis of 20 patients with non-Hodgkin lymphoma and autoimmune hemolytic anemia: A retrospective study.

Authors:  Ji-Cheng Zhou; Mei-Qing Wu; Zheng-Mian Peng; Wei-Hua Zhao; Zhen-Jie Bai
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.